bnt 162b2 vaccine Search Results


bnt 162b2 vaccine  (LabCorp)
90
LabCorp bnt 162b2 vaccine
Characteristics of the studies describing the effectiveness and safety of SARS‐CoV‐2 vaccines in inflammatory Bowel Disease (IBD) patients
Bnt 162b2 Vaccine, supplied by LabCorp, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/bnt 162b2 vaccine/product/LabCorp
Average 90 stars, based on 1 article reviews
bnt 162b2 vaccine - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

Image Search Results


Characteristics of the studies describing the effectiveness and safety of SARS‐CoV‐2 vaccines in inflammatory Bowel Disease (IBD) patients

Journal: Alimentary Pharmacology & Therapeutics

Article Title: Effectiveness and safety of SARS‐CoV‐2 vaccine in Inflammatory Bowel Disease patients: a systematic review, meta‐analysis and meta‐regression

doi: 10.1111/apt.16913

Figure Lengend Snippet: Characteristics of the studies describing the effectiveness and safety of SARS‐CoV‐2 vaccines in inflammatory Bowel Disease (IBD) patients

Article Snippet: Ben Tov et al,2021 , Multicentre, retrospective cohort , Israel , Data from Maccabi Healthcare services between December 2020 and March 2021 including 12,231 IBD patients , Age ≥ 16 years with diagnosis of IBD based on the registry , BNT 162b2 Vaccine , Anti‐receptor binding domain IgG antibodies specific to SARS‐CoV‐2 using the LabCorp Cov2Quant IgG assay.

Techniques: Vaccines, Biomarker Discovery, Binding Assay, Infection, Medications, Enzyme-linked Immunosorbent Assay

Studies describing seroconversion after SARS‐CoV‐2 vaccination in inflammatory Bowel Disease patients

Journal: Alimentary Pharmacology & Therapeutics

Article Title: Effectiveness and safety of SARS‐CoV‐2 vaccine in Inflammatory Bowel Disease patients: a systematic review, meta‐analysis and meta‐regression

doi: 10.1111/apt.16913

Figure Lengend Snippet: Studies describing seroconversion after SARS‐CoV‐2 vaccination in inflammatory Bowel Disease patients

Article Snippet: Ben Tov et al,2021 , Multicentre, retrospective cohort , Israel , Data from Maccabi Healthcare services between December 2020 and March 2021 including 12,231 IBD patients , Age ≥ 16 years with diagnosis of IBD based on the registry , BNT 162b2 Vaccine , Anti‐receptor binding domain IgG antibodies specific to SARS‐CoV‐2 using the LabCorp Cov2Quant IgG assay.

Techniques: Medications, Vaccines

Outcomes of studies describing breakthrough CoV‐19 infection in vaccinated inflammatory Bowel Disease (IBD) patients

Journal: Alimentary Pharmacology & Therapeutics

Article Title: Effectiveness and safety of SARS‐CoV‐2 vaccine in Inflammatory Bowel Disease patients: a systematic review, meta‐analysis and meta‐regression

doi: 10.1111/apt.16913

Figure Lengend Snippet: Outcomes of studies describing breakthrough CoV‐19 infection in vaccinated inflammatory Bowel Disease (IBD) patients

Article Snippet: Ben Tov et al,2021 , Multicentre, retrospective cohort , Israel , Data from Maccabi Healthcare services between December 2020 and March 2021 including 12,231 IBD patients , Age ≥ 16 years with diagnosis of IBD based on the registry , BNT 162b2 Vaccine , Anti‐receptor binding domain IgG antibodies specific to SARS‐CoV‐2 using the LabCorp Cov2Quant IgG assay.

Techniques: Infection, Comparison, Control